Craig A. Johnson - 21 Nov 2025 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship
Director
Issuer ticker
AUPH
Reported as of
21 Nov 2025
Net transaction value
-$94,692
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Nov 2025, 17:17:53 UTC
Prior SEC filing
16 May 2025
Next SEC filing
03 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Craig Johnson

Key filing fact

Craig A. Johnson filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 24 Nov 2025.

Key facts

  • This page summarizes Craig A. Johnson's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 24 Nov 2025, 17:17.

Change

  • Previous filing in this sequence was filed on 16 May 2025.
  • Current net transaction value: -$94,692.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370348 Primary reporting owner

Johnson Craig A

Relationship
Director
Address
#140, 14315 - 118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature
/s/ Craig Johnson
Signature date
24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Shares

Tax liability

Transaction value
$94,692
Shares
-6,039
Change %
-29%
Price
$15.68
Shares after
14,592
Date
21 Nov 2025
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .